| Dr James Orson Barlow, MD | |
|
14800 W Mountain View Blvd Ste 160, Surprise, AZ 85374-2700 | |
| (623) 584-3376 | |
| (623) 584-3375 |
| Full Name | Dr James Orson Barlow |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 24 Years |
| Location | 14800 W Mountain View Blvd Ste 160, Surprise, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982683405 | NPI | - | NPPES |
| AZ0447670 | Other | AZ | BLUE CROSS BLUE SHIELD |
| 998007000014 | Other | AZ | MEDISUN |
| 188961600 | Other | AZ | DEPT OF LABOR WORK COMP |
| 1982683405 | Other | AZ | AHCCS |
| 7436767 | Other | AZ | AETNA |
| 229874 | Other | AZ | HEALTHNET |
| 2540678 | Other | AZ | UNITED HEALTHCARE |
| P00322854 | Other | AZ | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 29708 (Arizona) | Secondary |
| 207ND0101X | Dermatology - Mohs-micrographic Surgery | 29708 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arizona Dermatology Specialists, Pllc | 6204085145 | 5 |
News Archive
A study published today in JAMA (October 21) by Nancy M. Albert and colleagues, exploring aldosterone antagonist usage among US patients hospitalised with heart failure, found that only one-third of patients meeting current US Clinical Practice Guidelines criteria were actually being treated.
China's latest census shows that the proportion of elderly people in the country has increased, while the proportion of young people dropped significantly, but "leaders are refusing to relax strict family planning controls that are part of the cause," the Associated Press reports (4/28).
Cancer Council Queensland will today launch an Australia-first study into cancer survivorship, to benefit millions of Australians expected to survive cancer in their lifetime.
CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications.
Advances in screening for disease detection, better surgical techniques available to more women, and an increased number of therapies that reduce the risk of relapse in patients with both locally advanced and early stage disease, have collectively contributed to dramatic improvements in breast cancer's survival rates, according to a review of 60 years of patient records at The University of Texas MD Anderson Cancer Center.
› Verified 3 days ago
| Entity Name | Arizona Dermatology Specialists, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992061162 PECOS PAC ID: 6204085145 Enrollment ID: O20121009000421 |
News Archive
A study published today in JAMA (October 21) by Nancy M. Albert and colleagues, exploring aldosterone antagonist usage among US patients hospitalised with heart failure, found that only one-third of patients meeting current US Clinical Practice Guidelines criteria were actually being treated.
China's latest census shows that the proportion of elderly people in the country has increased, while the proportion of young people dropped significantly, but "leaders are refusing to relax strict family planning controls that are part of the cause," the Associated Press reports (4/28).
Cancer Council Queensland will today launch an Australia-first study into cancer survivorship, to benefit millions of Australians expected to survive cancer in their lifetime.
CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications.
Advances in screening for disease detection, better surgical techniques available to more women, and an increased number of therapies that reduce the risk of relapse in patients with both locally advanced and early stage disease, have collectively contributed to dramatic improvements in breast cancer's survival rates, according to a review of 60 years of patient records at The University of Texas MD Anderson Cancer Center.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Orson Barlow, MD 14800 W Mountain View Blvd Ste 160, Surprise, AZ 85374-2700 Ph: (623) 584-3376 | Dr James Orson Barlow, MD 14800 W Mountain View Blvd Ste 160, Surprise, AZ 85374-2700 Ph: (623) 584-3376 |
News Archive
A study published today in JAMA (October 21) by Nancy M. Albert and colleagues, exploring aldosterone antagonist usage among US patients hospitalised with heart failure, found that only one-third of patients meeting current US Clinical Practice Guidelines criteria were actually being treated.
China's latest census shows that the proportion of elderly people in the country has increased, while the proportion of young people dropped significantly, but "leaders are refusing to relax strict family planning controls that are part of the cause," the Associated Press reports (4/28).
Cancer Council Queensland will today launch an Australia-first study into cancer survivorship, to benefit millions of Australians expected to survive cancer in their lifetime.
CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications.
Advances in screening for disease detection, better surgical techniques available to more women, and an increased number of therapies that reduce the risk of relapse in patients with both locally advanced and early stage disease, have collectively contributed to dramatic improvements in breast cancer's survival rates, according to a review of 60 years of patient records at The University of Texas MD Anderson Cancer Center.
› Verified 3 days ago
Lynn Leroy Juracek, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14239 W Bell Rd, Suite 101, Surprise, AZ 85374 Phone: 623-544-7755 Fax: 623-544-8665 | |
Jesse M Olmedo, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14800 W Mountain View Blvd, Suite 160, Surprise, AZ 85374 Phone: 623-584-3376 Fax: 623-584-3375 | |
Dr. Susan Il Iorio, MD Dermatology Medicare: May Accept Medicare Assignments Practice Location: 14725 W Mountain View Blvd Ste 103, Surprise, AZ 85374 Phone: 623-243-9077 Fax: 623-544-8665 | |
Dr. Drew Aubrey Reese, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14800 W Mountain View Blvd Ste 160, Surprise, AZ 85374 Phone: 623-584-3376 Fax: 623-584-3375 | |
Kevin Nethers, M.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 14725 W Mountain View Blvd, Surprise, AZ 85374 Phone: 623-243-9077 Fax: 623-271-9826 |